The Europe Plasma Fractionation Market is expected to grow from US$ 6,824.67 million in 2021 to US$ 10,402.95 million by 2028; it is estimated to grow at a CAGR of 6.2% from 2021 to 2028.

Europe's Plasma Fractionation Market: Growth Drivers and COVID-19 Impact

The Europe plasma fractionation market is a significant and growing segment within the global healthcare industry, encompassing the consolidated markets of Germany, France, the UK, Spain, Italy, and the rest of Europe. This region is poised for robust growth in the coming years, driven by several key factors.

Europe Plasma Fractionation Market: Key Market Drivers

A rising geriatric population across Europe is a primary catalyst for market expansion. As the population ages, the incidence of chronic diseases that benefit from plasma-derived therapies increases. There's also an expanding use of immunoglobulins in various therapeutic areas, including:

• Neurology
• Hematology
• Rare genetic disorders
• Autoimmune disorders

Furthermore, the growing demand for plasma-derived therapies for managing a wide range of diseases, coupled with a surge in plasma therapies for disease management, are all contributing to this upward trend. European companies are actively investing in research and development to launch novel plasma therapy approaches, further fueling market growth.

Impact of COVID-19: Europe Plasma Fractionation Market

The COVID-19 pandemic has significantly altered medical practices in Europe, particularly concerning chronic diseases like neurological, hematological, and respiratory conditions. With medical staff re-prioritizing and focusing on critically ill patients, there have been shifts in illness detection and treatment for non-COVID conditions.

However, the pandemic has also created new opportunities for the plasma fractionation market. Many research organizations are now dedicated to COVID-19 studies, seeking to understand the virus better. Several federal agencies in Europe have proactively adopted plasma therapy to treat COVID-19 patients. For example, France's National Agency for Medicines and Health Products Safety (ANSM) authorized the use of immune plasma therapy for critically ill patients, and the European Commission recommended the emergency use of convalescent plasma therapy. This adoption of plasma therapies for COVID-19 management has had a positive impact on the market to some extent.

Despite this, the overall focus of pharmaceutical and biopharmaceutical companies has largely shifted towards developing novel COVID-19 treatments. This reallocation of resources has, to some extent, negatively impacted the development and growth within other therapeutic areas previously reliant on plasma-derived therapies.

Europe Plasma Fractionation Market Segmentation

Europe Plasma Fractionation Market -By Product

• Immunoglobulin
• Intravenous Immunoglobulin (IVIG)
• Subcutaneous Immunoglobulin (SCIG)
• Albumin
• Coagulation Factor Concentrates
• Protease Inhibitors
• Other

Europe Plasma Fractionation Market - By Application

• Neurology
• Immunology
• Hematology
• Critical Care
• Pulmonology
• Others

Europe Plasma Fractionation Market - By End User

• Hospitals and Clinics
• Clinical Research Laboratories
• Academic Institutes

Europe Plasma Fractionation Market - By Country

• France
• Germany
• Italy
• Spain
• UK
• Rest of Europe

Europe Plasma Fractionation Market - Company Profiles

• Bharat Serums and Vaccines Limited (BSV)
• Bio Products Laboratory Ltd.
• Biotest AG.
• CSL Limited
• Grifols, S.A.
• Kedrion S.p.A
• Octapharma AG
• Sanquin
• SK Plasma

Europe Plasma Fractionation Market Strategic Insights

Strategic insights for the Europe Plasma Fractionation provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Europe Plasma Fractionation Market Regional Insights

The geographic scope of the Europe Plasma Fractionation refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

About Us:

Business Market Insights is a market research platform that provides subscription service for industry and company reports. Our research team has extensive professional expertise in domains such as Electronics & Semiconductor; Aerospace & Defense; Automotive & Transportation; Energy & Power; Healthcare; Manufacturing & Construction; Food & Beverages; Chemicals & Materials; and Technology, Media, & Telecommunications.

Author’s Bio:

Suryakant Gadekar

Senior Market Research Expert at Business Market Insights